021-51111890
购物车（）
sales@molnova.cn
T247
CAS No. 1451042-18-4
T247 ( T 247;HDAC3 inhibitor T247 )
产品货号. M11944 CAS No. 1451042-18-4
A potent and selective HDAC3 inhibitor with IC50 of 0.24 uM, >75-fold selectivity over HDAC1 and no activity against HDAC4/6/8.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 50MG | ￥8991 | 有现货 |
|
| 100MG | ￥13041 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称T247
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent and selective HDAC3 inhibitor with IC50 of 0.24 uM, >75-fold selectivity over HDAC1 and no activity against HDAC4/6/8.
-
产品描述A potent and selective HDAC3 inhibitor with IC50 of 0.24 uM, >75-fold selectivity over HDAC1 and no activity against HDAC4/6/8; induces dose-dependent selective increase of NF-κB acetylation in human colon cancer HCT116 cells, induces growth inhibition of cancer cells, and activates HIV gene expression in latent HIV-infected cells; shows promising activity for anticancer and antiviral benefits; also decreases TMEM16A expression and functional activity in both prostatic cancer cell line PC-3 and the breast cancer cell line YMB-1.
-
同义词T 247;HDAC3 inhibitor T247
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC
-
研究领域——
-
适应症——
化学信息
-
CAS Number1451042-18-4
-
分子量389.48
-
分子式C21H19N5OS
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(NC1=CC=CC=C1N)C2=CC=C(C3=CN(CCC4=CSC=C4)N=N3)C=C2
-
化学全称N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1],[2],[3]triazol-4-yl]benzamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Suzuki T, et al. PLoS One. 2013 Jul 16;8(7):e68669.
2. Matsuba S, et al. J Pharmacol Exp Ther. 2014 Dec;351(3):510-8.
3. Methot JL, et al. Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8.
2. Matsuba S, et al. J Pharmacol Exp Ther. 2014 Dec;351(3):510-8.
3. Methot JL, et al. Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8.
产品手册
关联产品
-
LB-205
A Zn2+-dependent pan-inhibitor of class I and class II HDACs with a long half-life (12h) in vivo.
-
LMK-235
A selective HDAC5 and HDAC4 inhibitor with IC50 of 4.22 nM and 11.9 nM respectively.
-
Encorafenib
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
